Alessio Alogna, Leonhard Berboth, Alessandro Faragli, Jens Ötvös, Francesco Paolo Lo Muzio, Vittoria di Mauro, Jessica Modica, Eride Quarta, Lukas Semmler, Peter Maximilian Deißler, Yannic Wanja Berger, Khai Liem Tran, Beatrice de Marchi, Gianluigi Longinotti-Buitoni, Lorenzo Degli Esposti, Etienne Guillot, Didier Bazile, Michele Iafisco, Alessandro Dotti, Marie-Louise Bang, Claudio de Luca, Christina Brandenberger, Louise Benazzi, Dario di Silvestre, Antonella de Palma, Uwe Primeßnig, Felix Hohendanner, Simone Perna, Francesca Buttini, Paolo Colombo, Christian Mühlfeld, Paul Steendijk, Pierluigi Mauri, Carsten Tschöpe, Barry Borlaug, Burkert M Pieske, Philipp Attanasio, Heiner Post, Frank R Heinzel, Daniele Catalucci
BACKGROUND: The lack of disease-modifying drugs is one of the major unmet needs in patients with heart failure (HF). Peptides are highly selective molecules with the potential to act directly on cardiomyocytes. However, a strategy for effective delivery of therapeutics to the heart is lacking. OBJECTIVES: In this study, the authors sought to assess tolerability and efficacy of an inhalable lung-to-heart nano-in-micro technology (LungToHeartNIM) for cardiac-specific targeting of a mimetic peptide (MP), a first-in-class for modulating impaired L-type calcium channel (LTCC) trafficking, in a clinically relevant porcine model of HF...
January 2, 2024: Journal of the American College of Cardiology